Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27699094 | 0.92 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CYP19A1 | |
| SCHEMBL16163535 | 0.92 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3CYP19A1 | |
| SCHEMBL9821528 | 0.89 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL8362305 | 0.86 | MEN1 (0.33) | MEN1KMT2ACYP19A1 | |
| SCHEMBL11203592 | 0.80 | CYP19A1 (0.32) | MEN1KMT2ACYP19A1 | |
| SCHEMBL8366209 | 0.80 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL8632181 | 0.77 | — | — | |
| SCHEMBL11458345 | 0.75 | CYP19A1 (0.31) | MEN1KMT2ACYP19A1 | |
| SCHEMBL11458346 | 0.74 | — | — | |
| SCHEMBL7488337 | 0.71 | CHRM3 (0.33) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 802 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | claimed |
| US-20230203378-A1 | FORMULATIONS OF BIOREACHABLE DOPANTS FOR LIQUID CRYSTALS | KENT STATE UNIVERSITY | 2023-06-29 | — | — | US | claimed |
| US-20220025267-A1 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | ZYMERGEN ACQUISITION SUB, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3891252-A2 | BIOREACHABLE CHIRAL DOPANTS FOR LIQUID CRYSTAL APPLICATIONS | Zymergen Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| US-6602562-B2 | High dielectric anisotropy and clearing point with little impact on voltage holding ratio, low temperature stability and response time | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-08-05 | — | — | US | claimed |
| US-20030113482-A1 | Realignment layer; field has a component parallel to the liquid-crystal layer; positive dielectric anisotropy | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2003-06-19 | — | — | US | claimed |
| US-6217792-B1 | Chiral dopants | MERCK PATENT GMBH (DE) | 2001-04-17 | — | — | US | claimed |
| EP-0408995-B1 | Liquid crystal medium with limited temperature-dependence of the d/p coefficient | MERCK PATENT GMBH (DE) | 1995-11-08 | — | — | EP | claimed |
| US-5139698-A | Achiral liquid crystal compound with doping component | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-08-18 | — | — | US | claimed |
| US-11814563-B2 | Bioreachable chiral dopants for liquid crystal applications | ZYMERGEN INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230203378-A1 | FORMULATIONS OF BIOREACHABLE DOPANTS FOR LIQUID CRYSTALS | KENT STATE UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-109627658-B | Composition comprising functionalized polyvinyl alcohol and nanocapsules containing a liquid crystalline medium | 默克专利股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| EP-3638657-B1 | DIBENZOFURAN DERIVATIVES AND DIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2022-07-20 | — | — | EP | disclosed |
| WO-1989008649-A1 | HETEROCYCLIC 1,2-DIFLUOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989008632-A1 | DERIVATIVES OF 2,3-DIFLUOROPHENOL | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989008689-A1 | 2,3-DIFLUOROBENZENE DERIVATIVES AND THEIR USE AS COMPONENTS OF LIQUID CRYSTAL MEDIA | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| WO-1989008633-A1 | DIFLUOROBENZOL DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1989-09-21 | — | — | WO | disclosed |
| EP-0332007-A1 | Derivatives of 2,3-difluorohydroquinone | MERCK PATENT GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
| EP-0332024-A1 | Heterocyclic derivatives of 1,2-difluorobenzene | MERCK PATENT GmbH (DE) | 1989-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | DDT, MYT1, DBF4 | SLC6A2 2126/4885SLC6A4 2503/4885SLC6A3 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.